Transcriptomics

Dataset Information

29

Cardiac Effects of Rosiglitazone in Male Wistar Rats


ABSTRACT: Rosiglitazone, a peroxisome proliferator-activated receptor g (PPARg) agonist of the thiazolidinedione class, is a major insulin-sensitizing drug widely used to treat type-2 diabetes. Rosiglitazone causes myocardial hypertrophy in rodents and increases the risk of cardiac events in man. To better characterize its cardiac effects, male Wistar rats were orally administered 0, 10 or 80 mg/kg/day rosiglitazone. Overall design: Male Wistar rats were orally administered 0, 10 or 80 mg/kg/day rosiglitazone once per day for 14 days. Samples were obtained 6, 24, 168 or 336 hours after the final treatment.

INSTRUMENT(S): [Rat230_2] Affymetrix Rat Genome 230 2.0 Array

ORGANISM(S): Rattus norvegicus  

SUBMITTER: Mary Simcox  

PROVIDER: GSE22553 | GEO | 2010-06-25

SECONDARY ACCESSION(S): PRJNA128455

REPOSITORIES: GEO

Similar Datasets

2010-07-29 | E-GEOD-22553 | ArrayExpress
2018-04-18 | PXD004504 | Pride
| GSE68604 | GEO
| GSE68592 | GEO
2016-09-01 | E-GEOD-73387 | ArrayExpress
2012-07-13 | E-GEOD-39344 | ArrayExpress
| PRJNA128455 | ENA
2008-04-10 | E-GEOD-8485 | ArrayExpress
| GSE105073 | GEO
2008-01-24 | GSE8485 | GEO